View Filing Data

Document and Entity Information - USD ($)	12 Months Ended
Document and Entity Information - USD ($)	Dec. 31, 2016	Mar. 16, 2017	Jun. 30, 2016
Document And Entity Information [Abstract]
Entity Registrant Name	Semler Scientific, Inc.
Entity Central Index Key	0001554859
Trading Symbol	smlr
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding		5,313,568
Entity Public Float			$ 4,112,619.44
Document Type	10-K
Document Period End Date	Dec. 31, 2016
Amendment Flag	false
Document Fiscal Year Focus	2016
Document Fiscal Period Focus	FY

Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Current Assets:
Cash	$ 622	$ 405
Trade accounts receivable, net of allowance for doubtful accounts of $87 and $183 respectively	877	1,278
Prepaid expenses and other current assets	93	69
Total current assets	1,592	1,752
Assets for lease, net	875	830
Property and equipment, net	590	497
Long-term deposits	15
Total assets	3,072	3,079
Current liabilities:
Accounts payable	450	839
Accrued expenses	2,185	2,317
Deferred revenue	513	952
Loans payable, current portion	81
Total current liabilities	3,229	4,108
Long-term liabilities:
Deferred rent	35	43
Accrued interest	71
Accrued interest - related parties	124
Related party loan payable net of debt discount of $156 and $0, respectively	1,594
Loan payable net of debt discount of $65 and $0, respectively	938
Total long-term liabilities	2,762	43
Stockholders' deficit:
Common stock, $0.001 par value; 50,000,000 shares authorized; 5,148,568, and 5,148,568 shares issued, and 5,123,568 and 5,123,568 shares outstanding (treasury shares of 25,000 and 25,000, respectively)	5	5
Additional paid-in capital	21,998	21,291
Accumulated deficit	(24,922)	(22,368)
Total stockholders' deficit	(2,919)	(1,072)
Total liabilities and stockholders' deficit	$ 3,072	$ 3,079

Statements of Operations - USD ($) $ in Thousands	12 Months Ended
Statements of Operations - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Income Statement [Abstract]
Revenue	$ 7,434	$ 7,001
Total Revenue	7,434	7,001
Operating expenses:
Cost of revenue	1,873	2,847
Engineering and product development	866	1,436
Sales and marketing	3,827	6,266
General and administrative	3,027	4,871
Total operating expenses	9,593	15,420
Loss from operations	(2,159)	(8,419)
Interest expense	(391)	(86)
Other (expense) income	(4)	4
Other expense	(395)	(82)
Net loss	$ (2,554)	$ (8,501)
Net loss per share, basic and diluted (in dollars per share)	$ (0.50)	$ (1.72)
Weighted average number of shares used in computing basic and diluted loss per share (in shares)	5,123,568	4,928,881

Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) - USD ($) $ in Thousands	Common Stock	Treasury stock	Additional Paid-in Capital	Accumulated deficit	Total
Balance at Jan. 01, 2015	$ 5		$ 17,298	$ (13,867)	$ 3,436
Balance (in shares) at Jan. 01, 2015	4,741,017	(25,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common Stock Private Placements			1,374		1,374
Common Stock Private Placements (in shares)	400,500
Stock Option Exercises			14		$ 14
Stock Option Exercises (in shares)	7,051				7,051
Stock-based Compensation			2,605		$ 2,605
Net loss				(8,501)	(8,501)
Balance at Dec. 31, 2015	$ 5		21,291	(22,368)	(1,072)
Balance (in shares) at Dec. 31, 2015	5,148,568	(25,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of Warrants			407		407
Stock-based Compensation			300		300
Net loss				(2,554)	(2,554)
Balance at Dec. 31, 2016	$ 5		$ 21,998	$ (24,922)	$ (2,919)
Balance (in shares) at Dec. 31, 2016	5,148,568	(25,000)

Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
Statements of Cash Flows - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
CASH FLOWS FROM OPERATING ACTIVITIES:
Net Loss	$ (2,554)	$ (8,501)
Reconciliation of Net Loss to Net Cash Used in Operating Activities:
Amortization of debt discount	185	55
Depreciation	452	315
Loss on disposal of assets for lease	223	144
Allowance for doubtful accounts	108	272
Stock-based compensation expense	300	2,605
Changes in Operating Assets and Liabilities:
Trade accounts receivable	293	(1,195)
Prepaid expenses and other current assets	(38)	83
Accounts payable	(389)	750
Accrued expenses	55	997
Deferred revenue	(439)	340
Net Cash Used in Operating Activities	(1,804)	(4,135)
CASH FLOWS FROM INVESTING ACTIVITIES:
Additions to property and equipment	(223)	(532)
Change in restricted cash		2,100
Purchase of assets for lease	(591)	(572)
Net Cash (Used in) Provided by Investing Activities	(814)	996
CASH FLOWS FROM FINANCING ACTIVITIES:
Issuance of common stock		1,374
Proceeds from stock option exercise		14
Proceeds from loans payable	2,878
Payments of loans payable	(43)	(2,000)
Net Cash (Used in) Provided by Financing Activities	2,835	(612)
INCREASE (DECREASE) IN CASH	217	(3,751)
CASH, BEGINNING OF PERIOD	405	4,156
CASH, END OF PERIOD	622	405
Cash paid for interest	8	19
Supplemental disclosure of noncash financing activity:
Fair value of warrants issued to lenders	$ 407

Summary of Significant Accounting Policies and Estimates

12 Months Ended

Dec. 31, 2016

Accounting Policies [Abstract]

Summary of Significant Accounting Policies and Estimates

3. Summary of Significant Accounting Policies and Estimates

Basis for Presentation

The Company’s financial statements and accompanying notes are prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”).

Use of Estimates

The preparation of the accompanying financial statements in conformity with U.S. GAAP requires management to make certain estimates and assumptions that affect the amounts of assets and liabilities reported, disclosures about contingent assets and liabilities at the date of the financial statements, and reported amounts of revenues and expenses, and related disclosures during the reporting period. Significant items subject to such estimates include revenue recognition, allowance for doubtful accounts, valuation of equipment on lease, deferred tax asset valuation allowance, stock-based compensation and valuation of warrants. These estimates and assumptions are based on management’s best estimates and judgment. Management regularly evaluates its estimates and assumptions using historical experience and other factors; however, actual results could differ significantly from these estimates.

Revenue Recognition

The Company generates revenue primarily from the rental or license of its vascular testing product, or providing diagnostic testing service to its customers. The Company recognizes revenue from the licensing of its vascular testing product pursuant to agreements that automatically renew each month with revenue recognized on a daily convention basis. The Company’s arrangements with customers for its vascular testing product are normally on a month-to-month basis with fees billed at the rates established in the customer agreement. The Company recognizes revenue for providing diagnostic testing services on a per test basis to customers, as earned.

Accounts Receivable and Allowance for Doubtful Accounts

Accounts receivable are recorded at the invoiced amount, net of allowances for doubtful accounts. The allowance for doubtful accounts is based on management’s assessment of the collectability of accounts. The Company regularly reviews the adequacy of this allowance for doubtful accounts by considering historical experience, the age of the accounts receivable balances, the credit quality of the customers, current economic conditions, and other factors that may affect customers’ ability to pay to determine whether a specific allowance is appropriate. Accounts receivable deemed uncollectable are charged against the allowance for doubtful accounts when identified.

Assets for Lease

Assets for lease are recorded at cost. At December 31, 2016 and 2015, assets for lease consisted of vascular testing devices, which are leased to customers. The cost of such assets for lease is depreciated on a straight-line basis over 36 months for the units outstanding and recorded as cost of revenue.

The Company regularly reviews whether facts and circumstances exist which indicate that the carrying amounts of assets, may not be recoverable or that the useful life of assets are shorter or longer than originally estimated. The Company assesses the recoverability of its assets by comparing the projected undiscounted net cash flows associated with the related assets over their estimated remaining lives against their respective carrying amounts. The Company considers factors such as estimated usage and expected lives of its assets for lease in this analysis. Impairment, if any, is based on the excess of the carrying amount over the fair value of those assets. At December 31, 2016 and 2015, there were no impairment indicators.

Property and Equipment

Capital assets are recorded at cost. The cost of such capital assets is depreciated on a straight-line basis over a term depending on the assigned category (described below) and recorded as cost of revenue for WellChec capital assets and depreciation for all other capital assets recorded in engineering and product development, sales and marketing and general and administrative expenses.

At December 31, 2016 and 2015, capital assets are classified into one of the following categories:

Category Name			Description
Machinery & Equipment			Manufacturing, R&D, or other non-office equipment
Computer Equipment & Software			Software, computers, monitors, printers and other related equipment
Furniture & Fixtures			Office equipment and furniture owned by the company

At December 31, 2016 and 2015, capital assets are depreciated based on the following assumed useful life for each category:

Account Name			Useful Life
Machinery & Equipment			Five years
Computer Equipment & Software			Three years
Furniture & Fixtures			Five years

The Company regularly reviews whether facts and circumstances exist which indicate that the carrying amounts of capital assets, may not be recoverable or that the useful life of assets are shorter or longer than originally estimated. The Company assesses the recoverability of its assets by comparing the projected fair value of the related asset over the estimated remaining life against the respective carrying amounts. The Company considers factors such as estimated usage and expected lives of its capital assets in this analysis. Impairment, if any, is based on the excess of the carrying amount over the fair value of those assets. At December 31, 2016 and 2015, there were no impairment indicators.

Fair Value of Financial Instruments

Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of the fair value hierarchy under Financial Accounting Standards Board (the “FASB”) Accounting Standards Codification (“ASC”) 820, Fair Value Measurement, are described as follows:

Level 1 — Unadjusted quoted prices in active markets for identical assets or liabilities;

Level 2 — Inputs other than quoted prices included in Level I that are observable, unadjusted quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data; and

Level 3 — Unobservable inputs that are supported by little or no market activity, which requires the Company to develop its own models.

The financial instruments of the Company consist primarily of cash, accounts receivable, accounts payable, and loans payable of the Company. The carrying amounts of these items are considered a reasonable estimate of fair value at December 31, 2016 and 2015 due to their short term nature and their market interest rates.

Deferred Revenue

Deferred revenue represents amounts billed to or collected from customers for which the related revenues have not been recognized because one or more of the revenue recognition criteria have not been met. The full amount is expected to be recognized as revenues within one year from the balance sheet date and, therefore, such deferred amounts have been classified as current liabilities in the balance sheets presented. The Company generally invoices its clients in advance of a rental period with payment due upon receipt of the invoice.

Debt Discounts

In 2011, certain of the Company’s Directors personally guaranteed various loans or leases for the Company from First Republic Bank and U.S. Bancorp Business Equipment Finance Group, see Note 8. In consideration for the personal guarantees, these directors were given the opportunity to purchase fully vested warrants exercisable for common stock, which were determined to have a fair value of $425 at issuance. The debt discount is the fair value of the related warrants less the purchase price of the warrants. These leases were paid off early due to the opening of a new line of credit, resulting in acceleration of the expensing of the outstanding debt discount. These debt discounts were being amortized over the term of the loan or lease obligation. The amount amortized to interest expense was $55 in 2015. See Note 8.

In 2016, the Company secured promissory notes from various accredited investors. These accredited investors were given the opportunity to purchase fully vested warrants exercisable for common stock, which were determined to have a fair value of $407 at issuance which was recorded as debt discount. These debt discounts are being amortized to interest expense over the two-year life of the loan. The Company recognized $185 of interest expense associated with these discounts in 2016. See Note 8.

Research and Development

The Company expenses costs related to the research and development associated with the design, development, testing and enhancement of its products and services. Such expenses include salaries and related employee benefits, and fees paid to external service providers.

Stock-Based Compensation

Stock-based compensation expense is measured based on the grant-date fair value of the stock-based awards. The Company recognizes stock-based compensation expense for the portion of each option grant or stock award that is expected to vest over the estimated period of service and vesting. The Company uses the Black-Scholes option pricing model as the method for determining the estimated grant-date fair value of stock options. The Black-Scholes option pricing model requires the use of subjective assumptions which determine the fair value of stock-based awards, including the option’s expected volatility. In addition, the Company estimates the forfeiture rate of such awards during the requisite service period. Stock-based compensation expense is recognized on a straight-line basis over the requisite service period of the grant.

Employee Benefit Plan

The Company has a savings plan that qualifies under Section 401(k) of the Internal Revenue Code. There were no matching or discretionary employer contributions made to this plan during the years ended December 31, 2016 and 2015.

Income Taxes

The Company uses the asset and liability method to account for income taxes. Deferred tax assets and liabilities are recognized for the expected tax consequences attributable to the differences between financial reporting and the tax bases of existing assets and liabilities and net operating loss carry forwards, and they are measured using enacted tax rates expected to be in effect when differences are expected to reverse. A valuation allowance is recorded for loss carry-forwards and other deferred tax assets where it is more likely than not that such loss carry-forward and deferred tax assets will not be realized. The estimate for the valuation allowance for deferred tax assets requires management to make significant estimates and judgments about projected future operating results. If actual results differ from these projections or if management’s expectations of future results change, it may be necessary to adjust the valuation allowance.

Net Loss per Share

Basic and diluted net loss per common share is calculated by dividing the net loss by the weighted-average number of common shares outstanding during the periods. For the periods presented, the Company’s outstanding common stock equivalents consisted of options and warrants to purchase shares of common stock, all of which are antidilutive, and therefore were not included in the calculation for diluted loss per share.

Excise Tax Liability on Medical Devices

Recognition of the excise tax liability falls under ASC 450, Contingencies, because the tax is assessed on revenues. The Company recognized the excise tax when a rental payment was invoiced. Based on the guidance in ASC 605-45-50-3 and 50-4, these excise taxes are presented on a gross basis, included in revenue and general and administrative expenses. The Company incurred $0 and $136 related to this tax for the year ended December 31, 2016 and 2015, respectively. The excise tax was suspended for two years beginning in 2016. The excise tax is not an income tax.

Recently Issued Accounting Pronouncements

In May 2014, the FASB issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers. The amendment in this ASU provides guidance on the revenue recognition to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled inz exchange for those goods or services. The core principle of this update provides guidance to identify the performance obligations under the contract(s) with a customer and how to allocate the transaction price to the performance obligations in the contract. It further provides guidance to recognize revenue when (or as) the entity satisfies a performance obligation. This standard will replace most existing revenue recognition guidance. On August 8, 2015, the FASB issued ASU 2015-14, which defers the effective date of ASU No. 2014-09 by one year, and permits early adoption as long as the adoption date is not before the original public entity effective date. This standard is effective for the Company’s year ending December 31, 2019 with early adoption permitted for the year ended December 31, 2017. Since the issuance of ASU 2014-09, the FASB has issued several amendments which clarify certain points, including ASU 2016-08, Principal versus Agent Considerations (Reporting Revenue Gross versus Net), ASU 2016-10, Identifying Performance Obligations and Licensing, ASU 2016-11, Rescission of SEC Guidance Because of Accounting Standards Updates 2014-09 and 2014-16 Pursuant to Staff Announcements at the March 3, 2016 EITF Meeting, and ASU 2016-12, Narrow-Scope Improvements and Practical Expedients. The Company will adopt the new standard in the first quarter of fiscal year 2019. The Company is currently evaluating the method of adoption and effect the new standard will have on its financial statements.

In August 2014, the FASB issued ASU No. 2014-15, Presentation of Financial Statements-Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. This ASU provides guidance on management’s responsibility in evaluating whether there is substantial doubt about a Company’s ability to continue as a going concern and about related footnote disclosures. For each reporting period, management will be required to evaluate whether there are conditions or events that raise substantial doubt about the company’s ability to continue as a going concern within one year from the date the financial statements are issued. This standard is effective for annual periods ending after December 15, 2016, and for interim periods within annual periods beginning after December 15, 2016 with early adoption permitted. The Company will adopt the new standard in the first quarter of fiscal year 2017. The adoption of this standard is not anticipated to have a material impact on its financial statements.

In November 2015, the FASB issued ASU No. 2015-17, Balance Sheet Classification of Deferred Taxes (“ASU No. 2015-17”), to reduce complexity and simplify the reporting of deferred income tax liabilities and assets. Current GAAP requires an entity to separate deferred income tax liabilities into current and noncurrent amounts in a classified balance sheet. The amendments in this update require that deferred tax liabilities and assets be classified as noncurrent in a classified balance sheet. The current requirement that deferred tax liabilities and assets of a tax-paying component of an entity be offset and presented as a single amount is not affected by the amendment of this Update. This standard is effective for the Company’s annual periods beginning after December 15, 2017 and interim periods within annual periods beginning after December 15, 2018. The Company will adopt the new standard in fiscal year 2018. The Company maintains full valuation allowances on all deferred tax balances, and therefore, the adoption of this standard is not anticipated to have a material impact on its financial statements.

In January 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) (“ASU No. 2016-02”). Under the new guidance in ASU No. 2016-02, lessees will be required to recognize the following for all leases (with the exception of short-term leases) at the commencement date: 1) A lease liability, which is a lessee’s obligation to make lease payments arising from a lease, measured on a discounted basis; and 2) A right-of-use asset, which is an asset that represents the lessee’s right to use, or control the use of, a specified asset for the lease term. Under the new guidance, lessor accounting is largely unchanged, however, certain targeted improvements were made. ASU No. 2016-02 also simplifies the accounting for sale and leaseback transactions. Lessees (for capital and operating leases) and lessors (for sales-type, direct financing, and operating leases) must apply a modified retrospective transition approach for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. Lessees and lessors may not apply a full retrospective transition approach. This standard is effective for the Company’s annual periods beginning after December 15, 2019, including interim periods within those fiscal years. The Company will adopt the new standard in the first quarter of fiscal year 2020. The Company is currently evaluating the impact that this new standard will have on its financial statements.

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses of Financial Instruments. The new guidance changes the methodology for measuring credit losses on financial instruments and the timing of when such losses are recorded. This standard is effective for the Company’s fiscal years beginning after December 15, 2020. The Company will adopt the new standard in fiscal year 2021. The Company is currently evaluating the effect the new standard will have on its financial statements.

Commitments and Contingencies

12 Months Ended

Dec. 31, 2016

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

8. Commitments and Contingencies

Facilities Leases

The Company recognized facilities lease expenses of $70 and $209 for the years ended December 31, 2016 and 2015, respectively.

On September 23, 2014, the Company entered into a 36-month lease agreement for office space for the sales and marketing team located in Menlo Park, CA. The lease term commenced February 1, 2015 and is effective through January 31, 2018. Payments required under the terms of the lease are $17.0 per month from February 2015 to January 2016, $17.5 per month from February 2016 to January 2017, and $18.0 per month from February 2017 to January 2018. The Company anticipates total future lease payments of $215.4 for the year ended December 31, 2017; and $18.0 for the year ended December 31, 2018. On July 15, 2015, the Company entered into a 30-month sublease agreement for the Menlo Park office space, which commenced August 1, 2015 and is effective through the term of the lease, January 31, 2018. Payments required to the Company under the terms of the sublease are $15.5 per month from August 2015 to July 2016, $16.0 per month from August 2016 to July 2017, and $16.5 per month from August 2017 to January 2018. The Company anticipates receipt of total future sublease payments of $194.4 for the year ended December 31, 2017; and $16.5 for the year ended December 31, 2018. In 2015, the Company recorded an expense of $50, which represented the difference between estimated cash payments on the lease and cash receipts from the sublease. For the years ended December 31, 2016 and 2015, the Company recorded the resulting long-term liability as deferred rent of $35 and $43, respectively, on the Company’s balance sheet.

Loans Payable

	For the Year Ended December 31, 2016
Lender	Related Party		Long-term		Short-term
Chang Family Trust		1,000
Chang Family Trust		500
Glenhill Concentrated Long Master Fund, LLC		250
Accredited Investor				700
Accredited Investor				160
Accredited Investor				80
Ascentium Capital, LLC						22
Ascentium Capital, LLC				42		24
Royal Bank America Leasing, L.P.						25
Ascentium Capital, LLC				21		10
Total		1,750		1,003		81
Debt Discounts		(156)		(65)		—
Total, net of debt discounts		1,594		938		81

Loans from Related Parties

On January 15, 2016, the Company entered into a loan agreement with the Chang Family Trust, for which William H.C. Chang, a significant stockholder, is co-trustee. Pursuant to the loan agreement, the Company obtained a $1,000 unsecured loan for a 24-month term at a fixed interest rate of 10% per annum. Under the loan agreement, the Company will pay $1,000 of principal plus all accrued and unpaid interest at maturity. The Company may prepay the notes at any time prior to maturity without penalty. The notes must be repaid prior to maturity in the event of default, and the Company agreed not to incur additional indebtedness in excess of $50 without the lender’s prior consent, which is not to be unreasonably withheld. In connection therewith, the Company issued the Chang Family Trust a two-year warrant to purchase 114,286 shares of common stock at an exercise price of $1.75 per share. The warrants may not be exercised absent receipt of stockholder approval if after such exercise the holder would be the beneficial owner of more than 19.99% of the Company’s common stock. The relative fair value of this warrant was recorded as a debt discount on the Company’s balance sheet and partially offsets the total balance due for loans payable. As of the date of this filing, the Company is in compliance with all terms of this loan.

On January 21, 2016, the Company entered into a loan agreement with the Chang Family Trust, for which William H.C. Chang, a significant stockholder, is co-trustee. Pursuant to the loan agreement, the Company obtained a $500 unsecured loan for a 24-month term at a fixed interest rate of 5% per annum. Under the loan agreement, the Company will pay $500 of principal plus all accrued and unpaid interest at maturity. The Company may prepay the notes at any time prior to maturity without penalty. The notes must be repaid prior to maturity in the event of default, and the Company agreed not to incur additional indebtedness in excess of $50 without the lender’s prior consent, which is not to be unreasonably withheld. In connection therewith, the Company issued the Chang Family Trust a two-year warrant to purchase 114,286 shares of common stock at an exercise price of $1.75 per share. The warrants may not be exercised absent receipt of stockholder approval if after such exercise the holder would be the beneficial owner of more than 19.99% of the Company’s common stock. The relative fair value of this warrant was recorded as a debt discount on the Company’s balance sheet and partially offsets the total balance due for loans payable. As of the date of this filing, the Company is in compliance with all terms of this loan.

On November 21, 2016, the Company entered into a loan agreement with Glenhill Concentrated Long Master Fund, LLC, one of our significant stockholders. Pursuant to the loan agreement, the Company obtained a $250 unsecured loan for a 24-month term at a fixed interest rate of 10% per annum. Under the loan agreement, the Company will pay $250 of principal plus all accrued but unpaid interest at maturity. The notes may be prepaid at any time prior to maturity without penalty. The notes must be repaid prior to maturity in the event of default. In connection therewith, the Company issued the accredited investor a two-year warrant to purchase 28,378 shares of common stock at an exercise price of $1.85 per share. The warrants may not be exercised absent receipt of stockholder approval if after such exercise the holder would be the beneficial owner of more than 4.99% of the Company’s common stock. The relative fair value of this warrant was recorded as a debt discount on the Company’s balance sheet and partially offsets the total balance due for loans payable. As of the date of this filing, the Company is in compliance with all terms of this loan.

Other Loans

On September 30, 2014, the Company entered into a revolving line of credit with First Republic Bank. Pursuant to the line of credit agreement, the Company could borrow up to $2,000 for a 12-month term that had a variable annual interest rate based on First Republic’s Prime less a spread of 2.0% per annum. The initial interest rate was 1.25% per annum. Under the line of credit agreement, the Company made monthly payments consisting of $2 of interest, and an annual payment consisting of $2,002 principal plus any accrued interest. The line of credit agreement provided for customary events of default. This line of credit was secured by a $2,100 collateral cash account in the Company’s name at First Republic. The line of credit was retired and the collateral cash account was closed in September 2015.

On March 31, 2016, the Company entered into a loan agreement with an accredited investor. Pursuant to the loan agreement, the Company obtained a $700 unsecured loan for a 24-month term at a fixed interest rate of 10% per annum. Under the loan agreement, the Company will pay $700 of principal plus all accrued but unpaid interest at maturity. The notes may be prepaid at any time prior to maturity without penalty. The notes must be repaid prior to maturity in the event of default. In connection therewith, the Company issued the accredited investor a two-year warrant to purchase 79,459 shares of common stock at an exercise price of $1.85 per share. The warrants may not be exercised absent receipt of stockholder approval if after such exercise the holder would be the beneficial owner of more than 4.99% of the Company’s common stock. The relative fair value of this warrant was recorded as a debt discount on the Company’s balance sheet and partially offsets the total balance due for loans payable. As of the date of this filing, the Company is in compliance with all terms of this loan.

On April 5, 2016, the Company entered into a loan agreement with an accredited investor. Pursuant to the loan agreement, the Company obtained a $160 unsecured loan for a 24-month term at a fixed interest rate of 10% per annum. Under the loan agreement, the Company will pay $160 of principal plus all accrued but unpaid interest at maturity. The notes may be prepaid at any time prior to maturity without penalty. The notes must be repaid prior to maturity in the event of default. In connection therewith, the Company issued the accredited investor a two-year warrant to purchase 18,162 shares of common stock at an exercise price of $1.85 per share. The warrants may not be exercised absent receipt of stockholder approval if after such exercise the holder would be the beneficial owner of more than 4.99% of the Company’s common stock. The relative fair value of this warrant was recorded as a debt discount on the Company’s balance sheet and partially offsets the total balance due for loans payable. As of the date of this filing, the Company is in compliance with all terms of this loan.

On May 20, 2016, the Company entered into a loan agreement with an accredited investor. Pursuant to the loan agreement, the Company obtained a $80 unsecured loan for a 24-month term at a fixed interest rate of 10% per annum. Under the loan agreement, the Company will pay $80 of principal plus all accrued but unpaid interest at maturity. The notes may be prepaid at any time prior to maturity without penalty. The notes must be repaid prior to maturity in the event of default. In connection therewith, the Company issued the accredited investor a two-year warrant to purchase 9,081 shares of common stock at an exercise price of $1.85 per share. The warrants may not be exercised absent receipt of stockholder approval if after such exercise the holder would be the beneficial owner of more than 4.99% of the Company’s common stock. The relative fair value of this warrant was recorded as a debt discount on the Company’s balance sheet and partially offsets the total balance due for loans payable. As of the date of this filing, the Company is in compliance with all terms of this loan.

The Company uses the Black-Scholes pricing model to determine the relative fair market value of warrants. The relative fair market value of each warrant is estimated on the date of grant. There were no warrants issued during the year ended December 31, 2015. The fair value of all warrants issued in conjunction with the promissory notes during 2016 was $407. The relative fair value of the warrants granted is estimated on the date of grant using the Black-Scholes pricing model and the following assumptions for the periods presented:

			For the year ended December 31, 2016
Expected term (in years)			2
Risk-free interest rate			0.73 – 1.1%
Expected volatility			97.7 – 100%
Expected dividend rate.			0%

The assumptions are based on the following for each of the years presented:

Valuation Method — The Company estimates the relative fair value of warrants using the Black-Scholes pricing model.

Expected Term — The Company uses the amount of time the warrants are exercisable per the contractual terms of the award.

Volatility — The Company derives this number from the historical stock volatilities of the Company’s stock over a period approximately equal to the expected term of the warrants.

Risk-free Interest Rate — The risk-free interest rate is based on median U.S. Treasury zero coupon issues with remaining terms similar to the expected term on the warrants.

Expected Dividend — The Company has never declared or paid any cash dividends and does not plan to pay cash dividends in the foreseeable future, and therefore, used an expected dividend yield of zero in the valuation model.

On July 1, 2016, the Company entered into a software license financing agreement with Ascentium Capital, LLC. Pursuant to the agreement, the Company obtained a $39 loan for a 12-month term at a fixed interest rate of 8.9% per annum. to finance its upfront software licensing fee. The Company has no obligation to make any payments during the first three months, and agreed to pay $4.6 of principal and accrued interest for each of the last 9 months of the term. The loan may be prepaid at any time prior to maturity without penalty. The agreement provides for customary events of default. As of the date of this filing, the Company is in compliance with all terms of this loan.

On July 8, 2016, the Company entered into an additional software license financing agreement with Ascentium Capital, LLC. Pursuant to the agreement, the Company obtained a $74 loan for a 36-month term at a fixed interest rate of 8.9% per annum. Under the loan agreement, the Company agreed to make monthly payments of $2.4 of principal and accrued interest. The loan may be prepaid at any time prior to maturity without penalty. The agreement provides for customary events of default. As of the date of this filing, the Company is in compliance with all terms of this loan.

On July 11, 2016, the Company entered into a secured equipment financing agreement with Royal Bank America Leasing, L.P. Pursuant to the agreement, the Company obtained a $140 loan for a 36-month term at a fixed interest rate of 7.3% per annum, which is secured by related equipment. The loan is to be disbursed in three installments. The first installment was for $37. The second installment for $47 will be disbursed in July 2017, and the third installment for $56 will be disbursed in July 2018. Under the loan agreement, the Company will pay $3.5 of principal and accrued interest for each of the first 12 months, $4.4 of principal and accrued interest for each of months 13-24, and $5.3 of principal and accrued interest for each of months 25-36. The loan may be prepaid at any time only in accordance with the agreement. The agreement provides for customary events of default. As of the date of this filing, the Company is in compliance with all terms of this loan.

On October 2, 2016, the Company entered into a secured equipment financing agreement with Ascentium Capital, LLC. Pursuant to the agreement, the Company obtained a $33 loan for a 36-month term at a fixed interest rate of 9.1% per annum. Under the loan agreement, the Company agreed to make monthly payments of $1.0 of principal and accrued interest. The loan may be prepaid at any time prior to maturity without penalty. The agreement provides for customary events of default. As of the date of this filing, the Company is in compliance with all terms of this loan.

For the years ended December 31, 2016 and 2015, interest expense was $391 and $74, respectively, which included amortization of the debt discount of $185 and $55, respectively.

Indemnification Obligations

The Company enters into agreements with customers, partners, lenders, consultants, lessors, contractors, sales representatives and parties to certain transactions in the ordinary course of the Company’s business. These agreements may require the Company to indemnify the other party against third party claims alleging that its product infringes a patent or copyright. Certain of these agreements require the Company to indemnify the other party against losses arising from: a breach of representations or covenants, claims relating to property damage, personal injury or acts or omissions of the Company, its employees, agents or representatives. The Company has also agreed to indemnify the directors and certain of the officers and employees in accordance with the by-laws of the Company. These indemnification provisions will vary based upon the nature and terms of the agreements. In many cases, these indemnification provisions do not contain limits on the Company’s liability, and the occurrence of contingent events that will trigger payment under these indemnities is difficult to predict. As a result, the Company cannot estimate its potential liability under these indemnities. The Company believes that the likelihood of conditions arising that would trigger these indemnities is remote and, historically, the Company had not made any significant payment under such indemnification provisions. Accordingly, the Company has not recorded any liabilities relating to these agreements. In certain cases, the Company has recourse against third parties with respect to the aforesaid indemnities, and the Company believes it maintains adequate levels of insurance coverage to protect the Company with respect to potential claims arising from such agreements.

Stockholders' Deficit

12 Months Ended

Dec. 31, 2016

Stockholders' Equity Note [Abstract]

Stockholders' Deficit

9. Stockholders’ Deficit

Authorized Capital

In connection with the conversion to a Delaware corporation, during the quarter ended September 30, 2013, the Company’s certificate of incorporation was amended and restated to authorize the Company to issue up to 54,000,000 shares, of which 50,000,000 shares were designated as common stock with par value of $0.001 per share and 4,000,000 shares were designated as convertible preferred stock with par value of $0.001 par value per share. On October 30, 2015, the Company further amended and restated its certificate of incorporation and now has 50,000,000 authorized shares of capital stock, all of which are designated as common stock with par value of $0.001 per share.

A. Common Stock

Issuance of Common Stock

In February 2015, the Company completed a private placement in which it issued and sold 55,000 shares of its common stock at a price of $4.52 per share. The Company received proceeds of $248. In March 2015, the Company completed a private placement in which it issued and sold 62,500 shares of its common stock at a price of $4.00 per share. The Company received proceeds of $250. In April 2015, the Company completed a private placement in which it issued and sold 143,000 shares of its common stock at a price of $3.50 per share. The Company received proceeds of $501. In December 2015, the Company completed a private placement in which it issued and sold 140,000 shares of its common stock and warrants to purchase 28,000 shares of its common stock in exchange proceeds of $374.

Voting Rights of Common Stock

Each holder of shares of Common Stock is entitled to one vote for each share held.

Common Stock Warrants

In September 2015, the Company amended the terms of all of its outstanding warrants to acquire shares of its common stock (other than the underwriter warrants to acquire an aggregate of 71,500 shares) to provide that all such warrants expire July 31, 2023. The Company has recorded an expense of $363 as it relates to stock based compensation during the year ended December 31, 2015 for this change in expiration terms.

In December 2015, in connection with the closing of a private placement described above, the Company sold a 2-year warrant to acquire 28,000 shares of common stock at an exercise price of $1.75 per share.

In January 2016, the Company issued the Chang Family Trust a two-year warrant to purchase 114,286 shares of common stock at an exercise price of $1.75 per share. The warrants may not be exercised absent receipt of stockholder approval if after such exercise the holder would be the beneficial owner of more than 19.99% of the Company’s common stock. The relative fair value of this warrant was recorded as a debt discount on the Company’s balance sheet and partially offsets the total balance due for loans payable. Also in January 2016, the Company issued the Chang Family Trust a two-year warrant to purchase 114,286 shares of common stock at an exercise price of $1.75 per share. The warrants may not be exercised absent receipt of stockholder approval if after such exercise the holder would be the beneficial owner of more than 19.99% of the Company’s common stock. The relative fair value of this warrant was recorded as a debt discount on the Company’s balance sheet and partially offsets the total balance due for loans payable.

In March 2016, the Company issued the accredited investor a two-year warrant to purchase 79,459 shares of common stock at an exercise price of $1.85 per share. The warrants may not be exercised absent receipt of stockholder approval if after such exercise the holder would be the beneficial owner of more than 4.99% of the Company’s common stock. The relative fair value of this warrant was recorded as a debt discount on the Company’s balance sheet and partially offsets the total balance due for loans payable.

In April 2016, the Company issued the accredited investor a two-year warrant to purchase 18,162 shares of common stock at an exercise price of $1.85 per share. The warrants may not be exercised absent receipt of stockholder approval if after such exercise the holder would be the beneficial owner of more than 4.99% of the Company’s common stock. The relative fair value of this warrant was recorded as a debt discount on the Company’s balance sheet and partially offsets the total balance due for loans payable.

In May 2016, the Company issued the accredited investor a two-year warrant to purchase 9,081 shares of common stock at an exercise price of $1.85 per share. The warrants may not be exercised absent receipt of stockholder approval if after such exercise the holder would be the beneficial owner of more than 4.99% of the Company’s common stock. The relative fair value of this warrant was recorded as a debt discount on the Company’s balance sheet and partially offsets the total balance due for loans payable.

In November 2016, the Company sold a two-year warrant to purchase an aggregate of 28,378 shares of our common stock at an exercise price of $1.85 per share. The warrants may not be exercised, however, absent receipt of stockholder approval, if after such exercise the holder would be the beneficial owner of more than 4.99% of our common stock. The relative fair value of this warrant was recorded as a debt discount on the Company’s balance sheet and partially offsets the total balance due for loans payable.

Common Stock

For the years ended December 31, 2016 and 2015, a total of 2,800,883 and 2,297,625 shares of common stock, respectively, were reserved for issuance upon (i) exercise of common stock warrants, and (ii) the exercise of outstanding stock options, as follows:

	Year ended December 31,
	2016		2015
Common stock warrants		751,366		387,714
Options		2,049,517		1,909,911
Total		2,800,883		2,297,625

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74567-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(d))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

+ Details

Stock Option Plan

12 Months Ended

Dec. 31, 2016

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Stock Option Plan

10. Stock Option Plan

The Company’s stock-based compensation program is designed to attract and retain employees while also aligning employees’ interests with the interests of its stockholders. Stock options have been granted to employees under the stockholder-approved 2007 Key Person Stock Option Plan (“2007 Plan”) or the stockholder-approved 2014 Stock Incentive Plan (“2014 Plan”). Stockholder approval of the 2014 Plan became effective in September 2014. The 2014 Plan originally provided that the aggregate number of shares of common stock that may be issued pursuant to awards granted under the 2014 Plan may not exceed 450,000 shares (the “Share Reserve”), however in October 2015, the stockholders approved a 1,500,000 increase to the Share Reserve. In addition, the Share Reserve automatically increases on January 1st of each year, for a period of not more than 10 years, beginning on January 1st of the year following the year in which the 2014 Plan became effective and ending on (and including) January 1, 2024, in an amount equal to 4% of the total number of shares of common stock outstanding on December 31st of the preceding calendar year. The Company’s board of directors may act prior to January 1st of a given year to provide that there will be no January 1st increase in the Share Reserve for such year or that the increase in the Share Reserve for such year will be a lesser number of shares of common stock than would otherwise occur. The Share Reserve is currently 2,343,583 shares for the year ending December 31, 2016.

In light of stockholder approval of the 2014 Plan, the Company no longer grants equity awards under the 2007 Plan. As of December 31, 2016, 0 shares of an aggregate total of 407,500 shares were available for future stock-based compensation grants under the 2007 Plan and 686,515 shares of an aggregate total of 2,343,582 shares were available for future stock-based compensation grants under the 2014 Plan.

Aggregate intrinsic value represents the difference between the closing market value as of December 31, 2016 of the underlying common stock and the exercise price of outstanding, in-the-money options. A summary of the Company’s stock option activity and related information for 2016 and 2015 is as follows:

	Options Outstanding
	Number of Stock Options Outstanding		Weighted Average Exercise Price			Weighted Average Remaining Contractual Term (In Years)		Aggregate Intrinsic Value (in thousands)
Balance, January 1, 2015		649,500		$	1.49		7.44		$	474
Options granted		1,308,017			3.15
Options exercised		(7,051)			2.10				$	17
Options forfeited/cancelled		(40,555)			2.29
Balance, December 31, 2015		1,909,911		$	2.58		8.56		$	813
Options granted		160,000			2.23
Options forfeited/cancelled		(20,394)			2.23
Balance, December 31, 2016		2,049,517		$	2.58		7.66		$	306
Exercisable as of December 31, 2015		1,464,189		$	2.60		8.32		$	713
Exercisable as of December 31, 2016		1,643,417		$	2.60		7.66		$	306

The total compensation cost related to unvested stock option awards not yet recognized was $656 as of December 31, 2016. The weighted average period over which the total unrecognized compensation cost related to these unvested stock awards will be recognized is 2.4 years. The total number of unvested shares was 406,100 and 409,643 as of December 31, 2016 and 2015, respectively. The total estimated grant date fair value of unvested options was $1,092 and $2,484 as of December 31, 2016 and 2015, respectively. The total estimated grant date fair value of options vested during the years ended December 31, 2016 and 2015 was $300 and $2,605, respectively. The weighted average grant date fair value of options granted during the year ended December 31, 2016 is $1.43 per share or an aggregate grant date fair value of $229. The weighted average grant date fair value of options granted during the year ended December 31, 2015 is $2.08 per share or an aggregate grant date fair value of $2,722. The weighted average grand date fair value of options forfeited during the year ended December 31, 2016 was $30. The weighted average grant date fair value of options forfeited during the year ended December 31, 2015 was $61.

On January 1, 2015, the Company’s Compensation Committee granted an option to acquire an aggregate of 75,000 shares under the 2014 Plan. On May 1, 2015 the Company’s Compensation Committee granted options to acquire an aggregate of 50,000 shares under the 2014 Plan. On July 21, 2015, the Company’s Compensation Committee granted options to acquire an aggregate of 111,300 shares under the 2014 Plan. All of these options vest monthly over 48 months such that they are vested in full on the four-year anniversary of the grant date.

On July 21, 2015, the Company’s Compensation Committee approved the grant of options to acquire an aggregate of 730,500 shares under the 2014 Plan, contingent upon receipt of stockholder approval of an increase of 1,500,000 shares in the 2014 Plan Share Reserve (which approval was received on October 29, 2015). These options originally vested monthly over 12 months such that they are vested in full on the one-year anniversary of the October 29, 2015 grant effectiveness date. On July 31, 2015, the Company’s Compensation Committee granted options to the board of directors to acquire an aggregate of 35,000 shares under the 2014 Plan, which options vested in full on the grant date.

On December 31, 2015, the Company’s Compensation Committee granted options to the board of directors, including the CEO, to acquire an aggregate of 306,217 shares under the 2014 plan. Of these, 106,800 options vest monthly over 48 months such that they are vested in full on the four-year anniversary of the grant date. The remaining 199,417 options vested immediately upon grant.

In December 2015, the Company accelerated the vesting on 730,500 outstanding options such that they were vested in full as of December 31, 2015. The Company has recorded an expense of $1,062 as it relates to stock based compensation during the year ended December 31, 2015 for this change in vesting schedule.

In February 2016, the Company’s Compensation Committee granted options to the board of directors, including the CEO, to acquire an aggregate of 160,000 shares under the 2014 plan. Of these, 35,000 options vest annually on the 1-year anniversary of the grant date. The remaining 125,000 shares vest monthly over 48 months such that they are vested in full on the four-year anniversary of the grant date.

Determining the Fair Value of Stock Options

The fair value of the options granted is estimated on the date of grant using the Black-Scholes pricing model and the following assumptions for the periods presented:

	Year ended December 31,
	2016	2015
Expected term (in years)	5	5
Risk-free interest rate	1.28%	1.5 – 1.76%
Expected volatility	99.9%	80.7 – 83.3%
Expected dividend rate	0%	0%

The assumptions are based on the following for each of the years presented:

Valuation Method — The Company estimates the fair value of its stock options using the Black-Scholes option pricing model.

Expected Term — The Company estimates the expected term consistent with the simplified method identified by the Securities and Exchange Commission (“SEC”). The Company elected to use the simplified method because of its limited history of stock option exercise activity and its stock options meet the criteria of the “plain-vanilla” options as defined by the SEC. The simplified method calculates the expected term as the average of the vesting and contractual terms of the award.

Volatility — The Company derives this number from the historical stock volatilities of the Company’s stock over a period approximately equal to the expected term of the options.

Risk-free Interest Rate — The risk-free interest rate is based on median U.S. Treasury zero coupon issues with remaining terms similar to the expected term on the options.

Forfeiture — The Company estimates forfeitures at the time of grant and revises those estimates in subsequent periods if actual forfeitures differ from those estimates. The Company uses historical data to estimate pre-vesting forfeitures and records stock-based compensation expense only for those awards that are expected to vest. All stock-based payment awards are amortized on a straight-line basis over the requisite service periods of the awards, which are generally the vesting periods. If the Company’s actual forfeiture rate is materially different from its estimate, the stock-based compensation expense could be significantly different from what the Company has recorded in the current period.

The Company has recorded an expense of $300 and $2,605 as it relates to stock-based compensation for the years ended December 31, 2016 and 2015, respectively, which was allocated as follows based on the role and responsibility of the recipient in the Company:

	Year ended December 31,
	2016			2015
Cost of Revenue		$	2		$	2
Engineering and Product Development			47			101
Sales and Marketing			94			1,172
General and Administrative			157			1,330
Total		$	300		$	2,605

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References + Details

Summary of Significant Accounting Policies and Estimates (Policies)

12 Months Ended

Dec. 31, 2016

Accounting Policies [Abstract]

Basis for Presentation

The Company’s financial statements and accompanying notes are prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”).

Use of Estimates

Revenue Recognition

Accounts Receivable and Allowance for Doubtful Accounts

Assets for Lease

Property and Equipment

At December 31, 2016 and 2015, capital assets are classified into one of the following categories:

Category Name			Description
Machinery & Equipment			Manufacturing, R&D, or other non-office equipment
Computer Equipment & Software			Software, computers, monitors, printers and other related equipment
Furniture & Fixtures			Office equipment and furniture owned by the company

At December 31, 2016 and 2015, capital assets are depreciated based on the following assumed useful life for each category:

Account Name			Useful Life
Machinery & Equipment			Five years
Computer Equipment & Software			Three years
Furniture & Fixtures			Five years

Fair Value of Financial Instruments

Level 1 — Unadjusted quoted prices in active markets for identical assets or liabilities;

Level 3 — Unobservable inputs that are supported by little or no market activity, which requires the Company to develop its own models.

Deferred Revenue

Debt Discounts

Research and Development

Stock-Based Compensation

Employee Benefit Plan

Income Taxes

Net Loss per Share

Excise Tax Liability on Medical Devices

Recently Issued Accounting Pronouncements

Commitments and Contingencies (Detail) $ in Thousands	Dec. 31, 2016 USD ($)
Line of Credit Facility [Line Items]
Related Party, Total	$ 1,750
Related Party, Debt Discounts	(156)
Related Party, Total, net of debt discounts	1,594
Long-term, Total	1,003
Long-term, Debt Discounts	(65)
Long-term, Total, net of debt discounts	938
Short-term, Total	81
Short-term, Debt Discounts
Short-term, Total, net of debt discounts	81
Chang Family Trust
Line of Credit Facility [Line Items]
Related Party, Total	1,000
Chang Family Trust
Line of Credit Facility [Line Items]
Related Party, Total	500
Glenhill Concentrated Long Master Fund, LLC
Line of Credit Facility [Line Items]
Related Party, Total	250
Accredited Investor
Line of Credit Facility [Line Items]
Long-term, Total	700
Accredited Investor
Line of Credit Facility [Line Items]
Long-term, Total	160
Accredited Investor
Line of Credit Facility [Line Items]
Long-term, Total	80
Ascentium Capital, LLC
Line of Credit Facility [Line Items]
Short-term, Total	22
Ascentium Capital, LLC
Line of Credit Facility [Line Items]
Long-term, Total	42
Short-term, Total	24
Royal Bank America Leasing, L.P.
Line of Credit Facility [Line Items]
Short-term, Total	25
Ascentium Capital, LLC
Line of Credit Facility [Line Items]
Long-term, Total	21
Short-term, Total	$ 10

Commitments and Contingencies (Detail Textuals) - USD ($)		1 Months Ended	12 Months Ended
	Jul. 15, 2015	Sep. 23, 2014	Dec. 31, 2016	Dec. 31, 2015
Property Subject to or Available for Operating Lease [Line Items]
Accrued rent				$ 50,000
Facilities lease expense			$ 70,000	209,000
Deferred Rent			35,000	$ 43,000
Lease Agreement
Property Subject to or Available for Operating Lease [Line Items]
Term specified for lease agreement		36 months
Future lease payments for December 31, 2017			215,400
Future lease payments for December 31, 2018			18,000
Sub Lease Agreement
Property Subject to or Available for Operating Lease [Line Items]
Term specified for lease agreement	30 months
Future lease payments for December 31, 2017			194,400
Future lease payments for December 31, 2018			16,500
Lease term from February 2015 to January 2016 \| Lease Agreement
Property Subject to or Available for Operating Lease [Line Items]
Payments required per month under terms of lease agreement			17,000
Lease term from February 2016 to January 2017 \| Lease Agreement
Property Subject to or Available for Operating Lease [Line Items]
Payments required per month under terms of lease agreement			17,500
Lease term from February 2017 to January 2018 \| Lease Agreement
Property Subject to or Available for Operating Lease [Line Items]
Payments required per month under terms of lease agreement			18,000
Lease term from August 2015 to July 2016 \| Sub Lease Agreement
Property Subject to or Available for Operating Lease [Line Items]
Payments required per month under terms of lease agreement			15,500
Lease term from August 2016 to July 2017 \| Sub Lease Agreement
Property Subject to or Available for Operating Lease [Line Items]
Payments required per month under terms of lease agreement			16,000
Lease term from August 2017 to July 2018 \| Sub Lease Agreement
Property Subject to or Available for Operating Lease [Line Items]
Payments required per month under terms of lease agreement			$ 16,500

Commitments and Contingencies (Detail Textuals 1) - USD ($)							1 Months Ended								2 Months Ended	12 Months Ended
	Oct. 02, 2016	Jul. 11, 2016	Jul. 08, 2016	Jul. 01, 2016	Apr. 05, 2016	Jan. 15, 2016	Nov. 30, 2016	Nov. 21, 2016	May 20, 2016	Apr. 30, 2016	Mar. 31, 2016	Jan. 31, 2016	Jan. 21, 2016	Sep. 30, 2014	May 31, 2016	Dec. 31, 2016	Dec. 31, 2015
Commitments And Contingencies [Line Items]
Interest expense																$ 391,000	$ 74,000
Amortization of debt discount																185,000	55,000
Fair value of warrants issued to lenders																$ 407,000
Accredited Investor
Commitments And Contingencies [Line Items]
Exercise price per warrants							$ 1.85			$ 1.85					$ 1.85
Warrant term							2 years			2 years					2 years
Threshold limit of common stock on exceeding which need shareholders approval for exercising							4.99%			4.99%					4.99%
Number of common stock called by warrants							28,378			18,162					9,081
Chang Family Trust
Commitments And Contingencies [Line Items]
Exercise price per warrants												$ 1.75
Warrant term												2 years
Threshold limit of common stock on exceeding which need shareholders approval for exercising												19.99%
Number of common stock called by warrants												114,286
Software License Financing Agreement \| Ascentium Capital, LLC
Commitments And Contingencies [Line Items]
Amount of loan obtained			$ 74,000	$ 39,000
Term of loan			36 months	12 months
Annual fixed interest rate			8.90%	8.90%
Monthly principal plus accrued interest payment			$ 2,400	$ 4,600
Term of interest and principal payments				9 months
Secured Equipment Financing Agreement \| Royal Bank America Leasing, L.P.
Commitments And Contingencies [Line Items]
Amount of loan obtained		$ 140,000
Term of loan		36 months
Annual fixed interest rate		7.30%
First installment		$ 37,000
Second installment disbursed in July 2017		47,000
Third installment disbursed in July 2018		56,000
Principal and accrued interest for each of the first 12 months		3,500
Principal and accrued interest for each of the first 13-24 months		4,400
Principal and accrued interest for each of the first 25-36 months		$ 5,300
Secured Equipment Financing Agreement \| Ascentium Capital, LLC
Commitments And Contingencies [Line Items]
Amount of loan obtained	$ 33,000
Term of loan	36 months
Annual fixed interest rate	9.10%
Monthly principal plus accrued interest payment	$ 1,000
Secured Debt \| Line Of Credit Agreement \| First Republic Bank \| Revolving Credit Facility
Commitments And Contingencies [Line Items]
Maximum limit of borrowing														$ 2,000,000
Term of loan														12 months
Annual variable interest rate														2.00%
Description of interest rates														Prime rate
Annual fixed interest rate														1.25%
Monthly principal plus accrued interest payment														$ 2,002,000
Monthly interest payment														$ 2,000
Frequency of payment														Monthly
Restricted cash														$ 2,100,000
Unsecured Debt \| Loan Agreement \| Accredited Investor
Commitments And Contingencies [Line Items]
Amount of loan obtained					$ 160,000				$ 80,000		$ 700,000
Term of loan					24 months				24 months	24 months	24 months
Annual fixed interest rate					10.00%				10.00%		10.00%
Monthly principal plus accrued interest payment					$ 160,000				$ 80,000	$ 160,000	$ 700,000
Exercise price per warrants					$ 1.85				$ 1.85		$ 1.85
Warrant term					2 years				2 years		2 years
Threshold limit of common stock on exceeding which need shareholders approval for exercising					4.99%				4.99%		4.99%
Number of common stock called by warrants					18,162				9,081		79,459
Unsecured Debt \| Loan Agreement \| Glenhill Concentrated Long Master Fund, LLC
Commitments And Contingencies [Line Items]
Amount of loan obtained								$ 250,000
Term of loan								24 months
Annual fixed interest rate								10.00%
Monthly principal plus accrued interest payment								$ 250,000
Exercise price per warrants								$ 1.85
Warrant term								2 years
Threshold limit of common stock on exceeding which need shareholders approval for exercising								4.99%
Number of common stock called by warrants								28,378
Unsecured Debt \| Loan Agreement \| Chang Family Trust \| William H C Chang
Commitments And Contingencies [Line Items]
Amount of loan obtained						$ 1,000,000							$ 500,000
Term of loan						24 months							24 months
Annual fixed interest rate						10.00%							5.00%
Monthly principal plus accrued interest payment						$ 1,000,000							$ 500,000
Exercise price per warrants						$ 1.75							$ 1.75
Warrant term						2 years							2 years
Threshold limit of common stock on exceeding which need shareholders approval for exercising						19.99%							19.99%
Number of common stock called by warrants						114,286							114,286
Additional indebtness						$ 50,000							$ 50,000

Stockholders' Equity (Deficit) (Detail Textuals 1) - USD ($) $ / shares in Units, $ in Thousands		1 Months Ended									2 Months Ended	12 Months Ended
	Apr. 05, 2016	Nov. 30, 2016	May 20, 2016	Apr. 30, 2016	Mar. 31, 2016	Jan. 31, 2016	Sep. 30, 2015	Apr. 30, 2015	Mar. 31, 2015	Feb. 28, 2015	May 31, 2016	Dec. 31, 2016	Dec. 31, 2015
Stockholders Equity Deficit [Line Items]
Stock-based compensation expense												$ 300	$ 2,605
Number of shares in reserve												2,800,883	2,297,625
Chang Family Trust
Stockholders Equity Deficit [Line Items]
Threshold limit of common stock on exceeding which need shareholders approval for exercising						19.99%
Exercise price per warrants						$ 1.75
Number of common stock called by warrants						114,286
Warrant term						2 years
Accredited investors
Stockholders Equity Deficit [Line Items]
Threshold limit of common stock on exceeding which need shareholders approval for exercising		4.99%		4.99%							4.99%
Exercise price per warrants		$ 1.85		$ 1.85							$ 1.85
Number of common stock called by warrants		28,378		18,162							9,081
Warrant term		2 years		2 years							2 years
Unsecured Debt \| Accredited investors \| Loan Agreement
Stockholders Equity Deficit [Line Items]
Threshold limit of common stock on exceeding which need shareholders approval for exercising	4.99%		4.99%		4.99%
Exercise price per warrants	$ 1.85		$ 1.85		$ 1.85
Number of common stock called by warrants	18,162		9,081		79,459
Warrant term	2 years		2 years		2 years
Initial public offering \| Common Stock
Stockholders Equity Deficit [Line Items]
Stock-based compensation expense							$ 363
Underwriters option
Stockholders Equity Deficit [Line Items]
Number of common stock called by warrants							71,500
Private placement
Stockholders Equity Deficit [Line Items]
Number of common stock sold in IPO								143,000	62,500	55,000			140,000
Public offering price (in dollars per share)								$ 3.50	$ 4.00	$ 4.52
Net proceeds from issuance initial public offering								$ 501	$ 250	$ 248			$ 374
Exercise price per warrants													$ 1.75
Number of common stock called by warrants													28,000
Warrant term													2 years

Stock Option Plan - Summary of stock-based compensation activity (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Number of Stock Options Outstanding
Balance	1,909,911	649,500
Granted	160,000	1,308,017
Exercised		(7,051)
Forfeited/Cancelled	(20,394)	(40,555)
Balance	2,049,517	1,909,911
Exercisable	1,643,417	1,464,189
Weighted Average Exercise Price
Balance	$ 2.58	$ 1.49
Granted	2.23	3.15
Exercised		2.10
Forfeited/Cancelled	2.23	2.29
Balance	2.58	2.58
Exercisable	$ 2.60	$ 2.60
Weighted Average Remaining Contractual Term, Options Outstanding (in years)	7 years 7 months 28 days	8 years 6 months 22 days	7 years 5 months 9 days
Weighted Average Remaining Contractual Term, Options Exercisable (in years)	7 years 7 months 28 days	8 years 3 months 26 days
Aggregate Intrinsic Value, Options exercised		$ 17
Aggregate Intrinsic Value, Options Outstanding	$ 306	813	$ 474
Aggregate Intrinsic Value, Options Exercisable	$ 306	$ 713

Stock Option Plan (Detail Textuals) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended		12 Months Ended
	Oct. 31, 2015	Jul. 21, 2015	Dec. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares in reserve			2,800,883	2,297,625
Stock-based compensation expense			$ 300	$ 2,605
Total unrecognized compensation cost related to non-vested awards			$ 656
Weighted average period of unvested stock awards			2 years 4 months 24 days
Total estimated grant date fair value of options non-vested			$ 1,092	2,484
Total estimated grant date fair value of options vested			$ 300	$ 2,605
Weighted average grant date fair value of options granted			$ 1.43	$ 2.08
Weighted average grant date fair value of options forfeited			$ 30	$ 61
Aggregate grant date fair value			$ 229	$ 2,722
Total number of unvested shares			406,100	409,643
2007 Key Person Stock Option Plan ("2007 Plan") \| Employee stock option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of stock options vested			0
Aggregate number of shares			407,500
2014 Stock Incentive Plan ("2014 Plan") \| Employee stock option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of shares reserve increase			4.00%
Number of shares in reserve			2,343,583
Number of stock options vested			686,515
Aggregate number of shares			450,000
Additional authorized shares	1,500,000	730,500
Maximum term of stock option grants			10 years

Stock Option Plan (Detail Textuals 1) - USD ($) $ in Thousands		1 Months Ended					12 Months Ended
	Jan. 01, 2015	Feb. 28, 2016	Oct. 31, 2015	Jul. 31, 2015	Jul. 21, 2015	May 01, 2015	Dec. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense							$ 300	$ 2,605
Number of stock options granted							160,000	1,308,017
Number of stock option forfeited							20,394	40,555
Number of stock options exercised								7,051
2007 Key Person Stock Option Plan ("2007 Plan") \| Employee stock option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Aggregate number of shares							407,500
2014 Stock Incentive Plan ("2014 Plan") \| Board of Directors
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Aggregate number of shares				35,000
2014 Stock Incentive Plan ("2014 Plan") \| Employee stock option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Aggregate number of shares							450,000
Additional authorized shares			1,500,000		730,500
Number of stock options vested and exercisable					1,500,000
Stock-based compensation expense								$ 1,062
Number of stock options granted	75,000			35,000	111,300	50,000
Vesting period of option	48 months				48 months	48 months
Original vesting period of options					12 months
Options accelerated for vesting								730,500
2014 Stock Incentive Plan ("2014 Plan") \| Employee stock option \| Board of Directors
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of stock options vested and exercisable								106,800
Number of stock options granted								306,217
Vesting period of option								48 months
Number of options immediately vested								199,417
2014 Stock Incentive Plan ("2014 Plan") \| Employee stock option \| Chief Executive Officer
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of stock options vested and exercisable		35,000
Number of stock options granted		160,000
Vesting period of option		48 months
Number of options periodically vested		125,000

Income Taxes (Details 2) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Deferred tax assets:
Net operating loss carryforwards	$ 5,730	$ 4,732
Deferred Revenue	194	453
Depreciation and amortization	30	18
Stock-based compensation	1,089	1,105
Accrual and reserves	117	132
Research and Development Credits	96	130
Total gross deferred tax assets	7,256	6,570
Less valuation allowance	(7,256)	(6,570)
Net deferred tax assets

Balance Sheets (Parentheticals) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Statement of Financial Position [Abstract]
Allowance for doubtful accounts on trade accounts receivable (in dollars)	$ 87	$ 183
Related party loan payable, Debt Discounts	156
Loan payable debt discount	$ 65
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	50,000,000	50,000,000
Common stock, shares issued	5,148,568	5,148,568
Common stock, shares outstanding	5,123,568	5,123,568
Treasury stock, shares	25,000	25,000

The Company	12 Months Ended
The Company	Dec. 31, 2016
Company [Abstract]
The Company	1. The Company Semler Scientific, Inc. (the “Company”) was incorporated in the State of Oregon on August 9, 2007, established C-corporation status in 2012, and reincorporated as a Delaware corporation during 2013. The Company is an emerging growth company providing technology solutions to improve the clinical effectiveness and efficiency of healthcare providers. Its innovative and proprietary products and services assist its customers in evaluating and treating chronic diseases. In 2011, the Company began commercializing its first patented and U.S. Food and Drug Administration (“FDA”) cleared product, which measured arterial blood flow in the extremities to aid in the diagnosis of peripheral arterial disease (“PAD”). In March 2015, the Company received FDA 510(k) clearance for the next generation version of its product, QuantaFlo™, which the Company commercially launched in August 2015. In April 2015, the Company launched its multi-test service platform, WellChec™, to more comprehensively evaluate its customers’ patients for chronic disease. In October 2016, the Company shifted its marketing focus for WellChec™ from direct contracts with health insurance plans under which it acted as the primary WellChec™ service provider to contracts to supply its software and equipment to vendors who employ medical professionals to do annual wellness visits for health insurance plans. The Company did not record any WellChec™ revenue during 2016. The Company has one operating segment and generates revenue domestically primarily through direct licensing to direct customers. The Company is based in Portland, Oregon.

Going Concern	12 Months Ended
Going Concern	Dec. 31, 2016
Going Concern [Abstract]
Going Concern	2. Going Concern The Company has incurred recurring losses since inception and expects to continue to incur losses as a result of costs and expenses related to the Company’s marketing and other promotional activities, continued research and development of its products. As of December 31, 2016, the Company has negative working capital of $1,637, cash of $622 and stockholders’ deficit of $2,919. The Company’s principal sources of cash have included the issuance of equity securities, and to a lesser extent, borrowings under loan agreements and revenue from leasing its product. To increase revenues, the Company’s operating expenses will continue to grow and, as a result, the Company will need to generate significant additional revenues to achieve profitability. The Company’s financial statements as of December 31, 2016 have been prepared under the assumption that the Company will continue as a going concern. The Company’s ability to continue as a going concern is dependent upon its ability to attain further operating efficiencies and, ultimately, to generate additional revenue. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. The Company can give no assurances that additional capital that the Company is able to obtain, if any, will be sufficient to meet the Company’s needs. The foregoing conditions raise substantial doubt about the Company’s ability to continue as a going concern.

Concentration of Credit Risk	12 Months Ended
Concentration of Credit Risk	Dec. 31, 2016
Risks and Uncertainties [Abstract]
Concentration of Credit Risk	7. Concentration of Credit Risk Credit risk is the risk of loss from amounts owed by the financial counterparties. Credit risk can occur at multiple levels; as a result of broad economic conditions, challenges within specific sectors of the economy, or from issues affecting individual companies. Financial instruments that potentially subject the Company to credit risk consist of cash and accounts receivable. The Company maintains cash with major financial institutions. The Company’s cash consists of bank deposits held with banks that, at times, exceed federally insured limits. The Company limits its credit risk by dealing with counterparties that are considered to be of high credit quality and by performing periodic evaluations of the relative credit standing of these financial institutions. Concentration of credit risk with respect to accounts receivable is limited due to the large number of customers comprising the payer base. Management periodically monitors the creditworthiness of its customers and believes that it has adequately provided for any exposure to potential credit loss. For the year ended December 31, 2015, two customers accounted for, 14.2% and 11.8% of the Company’s revenue, respectively. As of December 31, 2015, two customers accounted for 19.4% and 13.3% of the Company’s accounts receivable, respectively. For the year ended December 31, 2016, one customer accounted for 15.1% of the Company’s revenue. As of December 31, 2016, three customers accounted for 24.2%, 15.1% and 13.7% of the Company’s accounts receivable, respectively. As of December 31, 2016 and 2015 the allowance for doubtful accounts was $87 and $183, respectively.

Subsequent Events	12 Months Ended
Subsequent Events	Dec. 31, 2016
Subsequent Events [Abstract]
Subsequent Events	13. Subsequent Events On January 23, 2017, the Company issued and sold 40,000 shares of its common stock to Glenhill Concentrated Long Master Fund, LLC, one of its significant stockholders, pursuant to a stock purchase agreement for $100,000, which was paid in cash. On February 13, 2017, the Company issued and sold an aggregate of 150,000 shares of its common stock to two accredited investors, including GPG RM Investment, LLC, an affiliate of one of its significant stockholders, pursuant to separate stock purchase agreements for an aggregate purchase price of $375,000, which was paid in cash. The Company relied on exemptions from registration contained in Section 4(a)(2) of the Securities Act, and Regulation D, Rule 506 thereunder, for the issuance and sale of the shares of common stock.

Going Concern (Detail Textuals) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015	Jan. 01, 2015
Going Concern [Abstract]
Negative working capital	$ (1,637)
Cash	622	$ 405	$ 4,156
Stockholders' deficit	$ (2,919)	$ (1,072)	$ 3,436

Summary of Significant Accounting Policies and Estimates (Detail Textuals) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Property, Plant and Equipment [Line Items]
Description of assets for lease	Assets for lease is depreciated on a straight-line basis over 36 months for the units outstanding and recorded as cost of revenue.
Fair value of warrants exercisable for common stock at issuance	$ 407	$ 425
Amortized interest expense	185	55
Excise tax	$ 0	$ 136
Machinery & Equipment
Property, Plant and Equipment [Line Items]
Capital assets depreciated assumed useful life	Five years
Computer Equipment & Software
Property, Plant and Equipment [Line Items]
Capital assets depreciated assumed useful life	Three years
Furniture & Fixtures
Property, Plant and Equipment [Line Items]
Capital assets depreciated assumed useful life	Five years

Assets for lease, net - Summary of assets for lease (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Leases, Capital [Abstract]
Assets for lease	$ 1,361	$ 1,280
Less: accumulated depreciation	(486)	(450)
Assets for lease, net	$ 875	$ 830

Property and Equipment, net (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Property, Plant and Equipment [Abstract]
Capital assets	$ 760	$ 542
Less: accumulated depreciation	(170)	(45)
Capital assets, net	$ 590	$ 497

Accrued Expenses - Summary of accrued expenses (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Accrued Liabilities, Current [Abstract]
Offering Costs	$ 227	$ 227
Compensation	1,481	1,093
Board of Director Fees	182	120
Miscellaneous Accruals	295	877
Total Accrued Expenses	$ 2,185	$ 2,317

Concentration of Credit Risk (Detail Textuals) $ in Thousands	12 Months Ended
	Dec. 31, 2016 USD ($) Customer	Dec. 31, 2015 USD ($) Customer
Concentration Risk [Line Items]
Allowance for doubtful accounts \| $	$ 87	$ 183
Sales revenue \| Customer concentration risk
Concentration Risk [Line Items]
Number of customers	1	2
Sales revenue \| Customer concentration risk \| Customer one concentration risk
Concentration Risk [Line Items]
Concentration risk percentage	15.10%	14.20%
Sales revenue \| Customer concentration risk \| Customer two concentration risk
Concentration Risk [Line Items]
Concentration risk percentage		11.80%
Accounts receivable \| Customer concentration risk
Concentration Risk [Line Items]
Number of customers	3	2
Accounts receivable \| Customer concentration risk \| Customer one concentration risk
Concentration Risk [Line Items]
Concentration risk percentage	24.20%	19.40%
Accounts receivable \| Customer concentration risk \| Customer two concentration risk
Concentration Risk [Line Items]
Concentration risk percentage	15.10%	13.30%
Accounts receivable \| Customer concentration risk \| Customer three concentration risk
Concentration Risk [Line Items]
Concentration risk percentage	13.70%

Stockholders' Equity (Deficit) (Detail Textuals) - $ / shares	Dec. 31, 2016	Dec. 31, 2015	Oct. 30, 2015	Sep. 30, 2013
Stockholders' Equity Note [Abstract]
Shares Authorized				54,000,000
Common stock, shares authorized	50,000,000	50,000,000	50,000,000	50,000,000
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001	$ 0.001	$ 0.001
Convertible preferred stock, shares authorized				4,000,000
Convertible preferred stock, par value (in dollars per share)				$ 0.001

Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
Income Taxes (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Current tax provision:
Federal
State	10	6
Deferred tax provision:
Federal
State
Total	$ 10	$ 6

Income Taxes (Details 1)	12 Months Ended
Income Taxes (Details 1)	Dec. 31, 2016	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Federal statutory rate	34.00%	34.00%
State income tax rate, net of federal benefit	(0.20%)	(0.05%)
Change in valuation allowance	(26.85%)	(33.95%)
Other	(7.26%)	(0.07%)
Effective income tax rate	(0.31%)	(0.07%)

Income Taxes (Detail Textuals) - USD ($) $ in Thousands	12 Months Ended
Income Taxes (Detail Textuals) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Tax Credit Carryforward [Line Items]
Net operating loss carryforwards for federal	$ 16,013
Net operating loss carryforwards for California	6,861
Income penalties expense	0	$ 0
Federal research and development
Tax Credit Carryforward [Line Items]
Federal research and development credit carryforwards	$ 98

Net loss per share attributable to common stockholders - Calculation of basic and diluted net loss per share (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Earnings Per Share [Abstract]
Net loss	$ (2,554)	$ (8,501)
Weighted average shares outstanding (in shares)	5,123,568	4,928,881
Basic and diluted loss per share (in dollars per share)	$ (0.50)	$ (1.72)

Net loss per share attributable to common stockholders - Summary of outstanding shares of common stock equivalents excluded from computation of diluted net loss per share (Details 1) - shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Weighted average shares outstanding:
Total	2,732,501	1,482,065
Common stock warrants
Weighted average shares outstanding:
Total	687,599	359,868
Options
Weighted average shares outstanding:
Total	2,044,902	1,122,197

Subsequent Events (Detail Textuals) - Subsequent event	1 Months Ended
Subsequent Events (Detail Textuals) - Subsequent event	Feb. 13, 2017 USD ($) Investor shares	Jan. 23, 2017 USD ($) shares
Glenhill Concentrated Long Master Fund, LLC \| Stock purchase agreement
Subsequent Event [Line Items]
Number of common stock shares issued and sold \| shares		40,000
Value of common stock shares issued and sold, paid in cash \| $		$ 100,000
Accredited investors
Subsequent Event [Line Items]
Number of common stock shares issued and sold \| shares	150,000
Value of common stock shares issued and sold, paid in cash \| $	$ 375,000
Number of accredited investors \| Investor	2